Legal & General Group Plc Has $4.89 Million Holdings in Arcus Biosciences, Inc. $RCUS

Legal & General Group Plc boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 15.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 205,203 shares of the company’s stock after purchasing an additional 26,806 shares during the quarter. Legal & General Group Plc owned 0.19% of Arcus Biosciences worth $4,890,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Decheng Capital LLC raised its stake in Arcus Biosciences by 242.3% during the 3rd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $7,447,000 after purchasing an additional 387,609 shares during the last quarter. WINTON GROUP Ltd acquired a new position in Arcus Biosciences during the 3rd quarter valued at $1,254,000. Candriam S.C.A. acquired a new position in Arcus Biosciences during the 3rd quarter valued at $5,147,000. Vanguard Group Inc. raised its stake in Arcus Biosciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 6,629,453 shares of the company’s stock valued at $90,161,000 after purchasing an additional 73,210 shares during the last quarter. Finally, Aberdeen Group plc acquired a new position in Arcus Biosciences during the 3rd quarter valued at $4,418,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Monday, April 20th. Citigroup increased their price objective on shares of Arcus Biosciences from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Wall Street Zen cut shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Morgan Stanley increased their price objective on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Monday, May 11th. Finally, Truist Financial began coverage on shares of Arcus Biosciences in a research note on Monday, May 18th. They issued a “buy” rating and a $35.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.10.

Arcus Biosciences Trading Down 0.2%

Shares of RCUS stock opened at $23.16 on Monday. Arcus Biosciences, Inc. has a 52-week low of $7.91 and a 52-week high of $28.72. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -7.28 and a beta of 0.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.04 and a current ratio of 4.04. The firm has a fifty day moving average of $23.84 and a 200-day moving average of $22.85.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The business had revenue of $17.00 million during the quarter, compared to analyst estimates of $29.49 million. Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The company’s quarterly revenue was down 39.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.14) EPS. On average, equities research analysts forecast that Arcus Biosciences, Inc. will post -3.61 earnings per share for the current fiscal year.

Insider Transactions at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,562 shares of Arcus Biosciences stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $25.77, for a total value of $66,022.74. Following the completion of the transaction, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,020,002.37. The trade was a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert C. Goeltz II sold 7,763 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $25.63, for a total value of $198,965.69. Following the completion of the transaction, the chief financial officer directly owned 84,161 shares in the company, valued at $2,157,046.43. The trade was a 8.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.

Key Stories Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: LifescI Capital maintained an Outperform rating on Arcus Biosciences and set a $46 price target, signaling meaningful upside from current levels.
• Neutral Sentiment: The analyst’s updated forecasts for 2026-2030 remain broadly consistent across periods, suggesting no major near-term change in the long-term view on the company’s earnings trajectory.
• Negative Sentiment: Despite the upbeat rating, Lifesci Capital expects negative EPS in every period it covered, including losses of about ($4.15) in FY2026 and ($4.55) in FY2027, reinforcing concerns about profitability.
• Negative Sentiment: The estimates sit below zero even in later years, with projected losses of roughly ($4.52) in FY2028, ($4.56) in FY2029, and ($4.45) in FY2030, which may be keeping pressure on the stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.